Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination

Not Recruiting

Trial ID: NCT01304303


Phase I study of SPARC1023 alone and in combination with carboplatin

Stanford Investigator(s)

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine


Inclusion Criteria:

   - Age ≥18 years

   - ECOG Performance Status ≤ 1.

   - Estimated life expectancy of at least 12-weeks;

   - Measurable disease as per RECIST guideline (Version 1.1);

Exclusion Criteria:

   - Any malignancy within past 5-years, except non-melanoma skin cancer, cervical
   intraepithelial neoplasia, or in situ cervical cancer

   - Known hypersensitivity to the study drugs

   - Treatment with any anti-cancer agents within 28 days of study entry

   - Presence of clinically evident active CNS metastases, including leptomeningeal
   involvement, requiring steroid or radiation therapy


drug: SPARC1023 I

drug: SPARC1023 II

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.